Rapid Medical’s Drivewire 24 Neurovascular Guidewire Approved in Europe

September 3, 2025—At the 2025 ESMINT annual meeting, Rapid Medical announced receipt of CE Mark approval under the European Medical Device Regulation—EU MDR—for its Drivewire 24 steerable guidewire.

The company noted that earlier this year, the Drivewire 24 device was introduced in North America through a limited commercial launch where it has been used in more than 1,000 neurovascular procedures. The company announced completion of the initial commercial cases in July 2024. In a multicenter North American analysis of 176 cases, the device successfully reached the target site in 94% of procedures with no device-related complications, reported Rapid Medical.

According to the company, the steerable 0.024-inch guidewire is designed with a deflectable, mechanically adjustable tip controlled by a proximal handle that enables operators to steer in real time, reaching tortuous anatomy directly, reducing wire exchanges, and supporting catheters more effectively in complex neurovascular procedures for the treatment of ischemic stroke, aneurysms, and other complex neurovascular conditions.

“In my experience, the wire provides a unique combination of precision and support that simply hasn’t been possible with conventional technologies,” commented Erez Nossek, MD, in the company’s press release. Dr. Nossek, who is a neurosurgeon at NYU Langone in New York, New York, added, “It has become a reliable tool that allows us to approach any anatomy with greater efficiency and less time.”

The company advised that European clinicians are now preparing for adoption of Drivewire 24, including Hozan Radhi, MD, an interventionalist at Örebro University Hospital in Örebro, Sweden, who received training on the device.

“It’s clear this technology can expedite our cases exponentially,” commented Dr. Radhi in the company’s press release. “The ability to control the tip in real time opens new options for access, precision, and support. I’m eager to integrate it into my daily practice and believe it will significantly change how we approach everyday cases.”